- Home
- KTTA vs SLRX Comparison
KTTA vs SLRX Comparison
Compare KTTA & SLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KTTA
- SLRX
- Stock Information
- Founded
- KTTA 2020
- SLRX N/A
- Country
- KTTA United States
- SLRX United States
- Employees
- KTTA N/A
- SLRX N/A
- Industry
- KTTA Biotechnology: Pharmaceutical Preparations
- SLRX Biotechnology: Pharmaceutical Preparations
- Sector
- KTTA Health Care
- SLRX Health Care
- Exchange
- KTTA Nasdaq
- SLRX Nasdaq
- Market Cap
- KTTA 5.5M
- SLRX 1.8M
- IPO Year
- KTTA 2021
- SLRX N/A
- Fundamental
- Price
- KTTA $0.68
- SLRX $0.75
- Analyst Decision
- KTTA
- SLRX
- Analyst Count
- KTTA 0
- SLRX 0
- Target Price
- KTTA N/A
- SLRX N/A
- AVG Volume (30 Days)
- KTTA 142.8K
- SLRX 3.6M
- Earning Date
- KTTA 08-12-2025
- SLRX 08-08-2025
- Dividend Yield
- KTTA N/A
- SLRX N/A
- EPS Growth
- KTTA N/A
- SLRX N/A
- EPS
- KTTA N/A
- SLRX N/A
- Revenue
- KTTA N/A
- SLRX N/A
- Revenue This Year
- KTTA N/A
- SLRX N/A
- Revenue Next Year
- KTTA N/A
- SLRX N/A
- P/E Ratio
- KTTA N/A
- SLRX N/A
- Revenue Growth
- KTTA N/A
- SLRX N/A
- 52 Week Low
- KTTA $0.67
- SLRX $0.45
- 52 Week High
- KTTA $7.50
- SLRX $7.20
- Technical
- Relative Strength Index (RSI)
- KTTA 32.67
- SLRX 41.73
- Support Level
- KTTA $0.67
- SLRX $0.66
- Resistance Level
- KTTA $0.77
- SLRX $0.90
- Average True Range (ATR)
- KTTA 0.04
- SLRX 0.12
- MACD
- KTTA 0.01
- SLRX -0.03
- Stochastic Oscillator
- KTTA 14.02
- SLRX 16.46
About KTTA Pasithea Therapeutics Corp.
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module).
About SLRX Salarius Pharmaceuticals Inc.
Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs. The company has focused on two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degradation. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.